BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 2005;93:453-457. [PMID: 16091764 DOI: 10.1038/sj.bjc.6602715] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011;81:360-368. [PMID: 20888135 DOI: 10.1016/j.ijrobp.2010.06.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
2 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ. The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts. Onco Targets Ther 2015;8:3513-21. [PMID: 26648743 DOI: 10.2147/OTT.S94082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
4 Zhao J, Lu B, Xu H, Tong X, Wu G, Zhang X, Liang A, Cong W, Dai J, Wang H. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology. 2008;48:265-275. [PMID: 18537194 DOI: 10.1002/hep.22280] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
5 Lukacova S, Overgaard J, Alsner J, Horsman MR. Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. Radiotherapy and Oncology 2006;80:165-71. [DOI: 10.1016/j.radonc.2006.07.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
6 Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709-717. [PMID: 16786357 DOI: 10.1007/s00432-006-0119-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
7 Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007;57:373-80. [PMID: 17513004 DOI: 10.1016/j.lungcan.2007.04.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
8 Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I. Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology 2009;14:716-22. [PMID: 19476604 DOI: 10.1111/j.1440-1843.2009.01536.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
9 Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K. Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer 2012;12:333. [PMID: 22853000 DOI: 10.1186/1471-2407-12-333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
10 Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, Du W, Zeng Y, Zhu J, Liu Z, Huang JA. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol 2020;13:169. [PMID: 33287873 DOI: 10.1186/s13045-020-01009-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011;15:1113-26. [PMID: 21718227 DOI: 10.1517/14728222.2011.594438] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
12 Chuang CY, Chang H, Lin P, Sun SJ, Chen PH, Lin YY, Sheu GT, Ko JL, Hsu SL, Chang JT. Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene 2012;492:262-9. [PMID: 22037483 DOI: 10.1016/j.gene.2011.10.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
13 Shiraishi T, Matsuyama S, Kitano H. Large-scale analysis of network bistability for human cancers. PLoS Comput Biol 2010;6:e1000851. [PMID: 20628618 DOI: 10.1371/journal.pcbi.1000851] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
14 Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol 2010;40:670-6. [PMID: 20382636 DOI: 10.1093/jjco/hyq041] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
15 Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM, Huang CC. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 2009;45:798-802. [PMID: 19213594 DOI: 10.1016/j.oraloncology.2008.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
16 Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clin Lung Cancer 2011;12:341-9. [PMID: 21703936 DOI: 10.1016/j.cllc.2011.03.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
17 Aravind T, Janardhanan M, Rakesh S, Savithri V, Unnikrishnan UG. Immunolocalization of osteopontin in dysplasias and squamous cell carcinomas arising from oral epithelium. J Oral Maxillofac Pathol 2017;21:18-23. [PMID: 28479681 DOI: 10.4103/0973-029X.203764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Mittal V. Epithelial Mesenchymal Transition in Aggressive Lung Cancers. In: Ahmad A, Gadgeel SM, editors. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Cham: Springer International Publishing; 2016. pp. 37-56. [DOI: 10.1007/978-3-319-24932-2_3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
19 Parker AL, Cox TR. The Role of the ECM in Lung Cancer Dormancy and Outgrowth. Front Oncol 2020;10:1766. [PMID: 33014869 DOI: 10.3389/fonc.2020.01766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
20 Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR; SWOG. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008;26:4771-6. [PMID: 18779603 DOI: 10.1200/JCO.2008.17.0662] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
21 Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006;6:237. [PMID: 17022822 DOI: 10.1186/1471-2407-6-237] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 4.2] [Reference Citation Analysis]
22 Han X, Wang W, He J, Jiang L, Li X. Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett 2019;17:2592-8. [PMID: 30854034 DOI: 10.3892/ol.2019.9905] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
23 Miao TW, Xiao W, Du LY, Mao B, Huang W, Chen XM, Li C, Wang Y, Fu JJ. High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer. FEBS Open Bio 2021;11:1237-49. [PMID: 33626243 DOI: 10.1002/2211-5463.13127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Frey AB, Wali A, Pass H, Lonardo F. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 2007;50:720-6. [DOI: 10.1111/j.1365-2559.2007.02675.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
25 Zhao M, Li X, Chen X. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation. J Bioenerg Biomembr 2021;53:177-89. [PMID: 33538941 DOI: 10.1007/s10863-021-09875-7] [Reference Citation Analysis]
26 Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, Chen CH, Huang CC. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck 2008;30:776-81. [PMID: 18228527 DOI: 10.1002/hed.20783] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
27 Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, Shimono M. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007;36:30-4. [PMID: 17181739 DOI: 10.1111/j.1600-0714.2006.00493.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
28 Wu XL, Lin KJ, Bai AP, Wang WX, Meng XK, Su XL, Hou MX, Dong PD, Zhang JJ, Wang ZY, Shi L. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells. World J Gastroenterol 2014; 20(30): 10440-10448 [PMID: 25132760 DOI: 10.3748/wjg.v20.i30.10440] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
29 Zhou Y, Mo S, Wang RH, Liu W, Liu J, Wang J, He J, Zhang H, Guan Z, Zhou S, Yu Y. Corn baked by burning coal triggered overexpression of osteopontin in hepatocytes of rats following fluorosis. Toxicol Ind Health 2012;28:195-202. [DOI: 10.1177/0748233711410905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Štemberger C, Matušan-ilijaš K, Avirović M, Bulat-kardum L, Ivančić A, Jonjić N, Lučin K. Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma. Acta Histochemica 2014;116:222-9. [DOI: 10.1016/j.acthis.2013.07.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
31 Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer 2010;103:1221-8. [PMID: 20859284 DOI: 10.1038/sj.bjc.6605865] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
32 Dai N, Bao Q, Lu A, Li J. Protein Expression of Osteopontin in Tumor Tissues Is an Independent Prognostic Indicator in Gastric Cancer. Oncology 2007;72:89-96. [DOI: 10.1159/000111108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
33 Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 2013;13:540. [PMID: 24215488 DOI: 10.1186/1471-2407-13-540] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
34 Zou XL, Wang C, Liu KE, Nie W, Ding ZY. Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis. Mol Clin Oncol 2015;3:633-8. [PMID: 26137280 DOI: 10.3892/mco.2015.517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
35 Xu C, Yuan Q, Wang W, Chi C, Zhang Q, Li L, Yang R, Wang Y. Prognostic significance of serum osteopontin levels in small cell lung cancer. BMC Pulm Med 2020;20:235. [PMID: 32873264 DOI: 10.1186/s12890-020-01242-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (Basel) 2020;12:E3379. [PMID: 33203146 DOI: 10.3390/cancers12113379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
37 Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007;11:81-90. [PMID: 17150036 DOI: 10.1517/14728222.11.1.81] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
38 Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 2008;10:277-82. [PMID: 18778551 DOI: 10.1007/s11912-008-0043-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
39 Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y, Li W. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol. 2011;137:1061-1070. [PMID: 21207061 DOI: 10.1007/s00432-010-0968-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
40 Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 2010;67:114-9. [PMID: 19376608 DOI: 10.1016/j.lungcan.2009.03.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
41 Thompson KJ, Deshmukh H, Solka JL, Weller JW. A white-box approach to microarray probe response characterization: the BaFL pipeline. BMC Bioinformatics 2009;10:449. [PMID: 20040098 DOI: 10.1186/1471-2105-10-449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009;4:338-347. [PMID: 19190517 DOI: 10.1097/jto.0b013e3181982abf] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
43 Shi L, Wang X. Role of osteopontin in lung cancer evolution and heterogeneity. Semin Cell Dev Biol 2017;64:40-7. [PMID: 27578008 DOI: 10.1016/j.semcdb.2016.08.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
44 Suwinski R, Giglok M, Galwas-Kliber K, Idasiak A, Jochymek B, Deja R, Maslyk B, Mrochem-Kwarciak J, Butkiewicz D. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer. BMC Cancer 2019;19:427. [PMID: 31068179 DOI: 10.1186/s12885-019-5617-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
45 Ouyang X, Huang Y, Jin X, Zhao W, Hu T, Wu F, Huang J. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. Onco Targets Ther 2018;11:5933-41. [PMID: 30275702 DOI: 10.2147/OTT.S164007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kerenidi T, Kazakou AP, Lada M, Tsilioni I, Daniil Z, Gourgoulianis KI. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9. Cancer Invest 2016;34:385-92. [PMID: 27624849 DOI: 10.1080/07357907.2016.1223301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
47 Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 2010;10:132. [PMID: 20377868 DOI: 10.1186/1471-2407-10-132] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
48 Liu C, Liu J, Wang X, Mao W, Jiang L, Ni H, Mo M, Wang W. Prognostic impact of nm23-H1 and PCNA expression in pathologic stage I non-small cell lung cancer. J Surg Oncol 2011;104:181-6. [PMID: 21495034 DOI: 10.1002/jso.21944] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
49 Liu F, Bai C, Guo Z. The prognostic value of osteopontin in limited-stage small cell lung cancer patients and its mechanism. Oncotarget 2017;8:70084-96. [PMID: 29050263 DOI: 10.18632/oncotarget.19589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
50 Polat B, Wohlleben G, Katzer A, Djuzenova C, Technau A, Flentje M. Influence of osteopontin silencing on survival and migration of lung cancer cells. Strahlenther Onkol 2013;189:62-7. [DOI: 10.1007/s00066-012-0238-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
51 Hsu MK, Pan CL, Chen FC. Functional divergence and convergence between the transcript network and gene network in lung adenocarcinoma. Onco Targets Ther 2016;9:335-47. [PMID: 26834492 DOI: 10.2147/OTT.S94897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL, Ma SC. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis. J Mol Histol 2014;45:533-40. [PMID: 24816798 DOI: 10.1007/s10735-014-9574-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
53 Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782-789. [PMID: 17148500 DOI: 10.1136/gut.2006.109868] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 4.4] [Reference Citation Analysis]